189 related articles for article (PubMed ID: 29880212)
1. Nanotechnology enabling the use of circulating tumor cells (CTCs) as reliable cancer biomarkers.
Hong S; Wang AZ
Adv Drug Deliv Rev; 2018 Feb; 125():1-2. PubMed ID: 29880212
[No Abstract] [Full Text] [Related]
2. Integration of biomimicry and nanotechnology for significantly improved detection of circulating tumor cells (CTCs).
Myung JH; Park SJ; Wang AZ; Hong S
Adv Drug Deliv Rev; 2018 Feb; 125():36-47. PubMed ID: 29247765
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology in Radiation Oncology.
Sun B; Hagan CT; Caster J; Wang AZ
Hematol Oncol Clin North Am; 2019 Dec; 33(6):1071-1093. PubMed ID: 31668207
[TBL] [Abstract][Full Text] [Related]
4. "Circulating Tumor Cells: Finding Rare Events for a Huge Knowledge of Cancer Dissemination".
Alix-Panabières C
Cells; 2020 Mar; 9(3):. PubMed ID: 32182830
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology in cancer diagnosis: progress, challenges and opportunities.
Zhang Y; Li M; Gao X; Chen Y; Liu T
J Hematol Oncol; 2019 Dec; 12(1):137. PubMed ID: 31847897
[TBL] [Abstract][Full Text] [Related]
6. Nanoplasmonic sensors for detecting circulating cancer biomarkers.
Ferhan AR; Jackman JA; Park JH; Cho NJ; Kim DH
Adv Drug Deliv Rev; 2018 Feb; 125():48-77. PubMed ID: 29247763
[TBL] [Abstract][Full Text] [Related]
7. Potential of circulating biomarkers in liquid biopsy diagnostics.
Yeo JC; Lim CT
Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
[No Abstract] [Full Text] [Related]
8. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay.
Alix-Panabières C; Pantel K
Expert Rev Mol Diagn; 2015; 15(11):1411-7. PubMed ID: 26390240
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic technologies for circulating tumour cells and exosomes.
Shao H; Chung J; Issadore D
Biosci Rep; 2015 Nov; 36(1):e00292. PubMed ID: 26604322
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor Cells: A New Window for Diagnosis and Evaluation of Cancer.
Liu M; Tang M; Li M; Gao F; Shi C; Hou J; Zeng W
Anticancer Agents Med Chem; 2016; 16(12):1529-1540. PubMed ID: 26902602
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells in the clinical cancer diagnosis.
Zhang P; Zhou H; Lu K; Wang Y; Feng T
Clin Transl Oncol; 2020 Mar; 22(3):279-282. PubMed ID: 31140068
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor Cells: Fluid Surrogates of Solid Tumors.
Thiele JA; Bethel K; Králíčková M; Kuhn P
Annu Rev Pathol; 2017 Jan; 12():419-447. PubMed ID: 28135562
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of circulating tumors cells: Biomarkers beyond enumeration.
Hwang WL; Pleskow HM; Miyamoto DT
Adv Drug Deliv Rev; 2018 Feb; 125():122-131. PubMed ID: 29326053
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of non-EpCAM based circulating tumor cell assays.
Austin RG; Huang TJ; Wu M; Armstrong AJ; Zhang T
Adv Drug Deliv Rev; 2018 Feb; 125():132-142. PubMed ID: 29366804
[TBL] [Abstract][Full Text] [Related]
15. New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use.
Becker TM; Caixeiro NJ; Lim SH; Tognela A; Kienzle N; Scott KF; Spring KJ; de Souza P
Int J Cancer; 2014 Jun; 134(11):2523-33. PubMed ID: 24122526
[TBL] [Abstract][Full Text] [Related]
16. Circulating Tumor DNA as a Cancer Biomarker: Fact or Fiction?
Leung F; Kulasingam V; Diamandis EP; Hoon DS; Kinzler K; Pantel K; Alix-Panabières C
Clin Chem; 2016 Aug; 62(8):1054-60. PubMed ID: 27259816
[No Abstract] [Full Text] [Related]
17. Circulating tumor cells (CTCs) as a liquid biopsy material and drug target.
Cai LL; Ye HM; Zheng LM; Ruan RS; Tzeng CM
Curr Drug Targets; 2014; 15(10):965-72. PubMed ID: 25182470
[TBL] [Abstract][Full Text] [Related]
18. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.
Wang H; Stoecklein NH; Lin PP; Gires O
Oncotarget; 2017 Jan; 8(1):1884-1912. PubMed ID: 27683128
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours.
Serrano Fernádez MJ; Alvarez Merino JC; Martínez Zubiaurre I; Fernández García A; Sánchez Rovira P; Lorente Acosta JA
Clin Transl Oncol; 2009 Oct; 11(10):659-68. PubMed ID: 19828408
[TBL] [Abstract][Full Text] [Related]
20. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
